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Cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous group of non-Hodgkin’s lymphoma character-
ized by an accumulation of malignant CD4 T cells in the skin. The group IIIa metal salt, gallium nitrate, is known
to have antineoplastic activity against B-cell lymphoma in humans, but its activity in CTCLs has not been
elaborated in detail. Herein, we examined the antineoplastic efficacy of a gallium compound, gallium maltolate
(GaM), in vitro and in vivo with murine models of CTCLs. GaM inhibited cell growth and induced apoptosis
of cultured CTCL cells. In human CTCL xenograft models, peritumoral injection of GaM limited the growth of
CTCL cells, shown by fewer tumor formations, smaller tumor sizes, and decreased neovascularization in tumor
microenvironment. To identify key signaling pathways that have a role in GaM-mediated reduction of tumor
growth, we analyzed inflammatory cytokines, as well as signal transduction pathways in CTCL cells treated by
GaM. IFN-g-induced chemokines and IL-13 were found to be notably increased in GaM-treated CTCL cells.
However, immunosuppressive cytokines, such as IL-10, were decreased with GaM treatment. Interestingly, both
oxidative stress and p53 pathways were involved in GaM-induced cytotoxicity. These results warrant further
investigation of GaM as a therapeutic agent for CTCLs.
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INTRODUCTION
Cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group
of peripheral, extranodal, non-Hodgkin’s lymphomas, resulting
in a variety of skin findings, including scaly red patches, plaques,
tumors, and erythroderma (Hwang et al., 2008). Patients
with tumor stage disease have a poor prognosis with a 5-year
survival of less than 50%. The treatment of CTCLs ranges
from skin-directed therapies for early disease to more complex
chemotherapy-based treatments for later stages (Hwang et al.,
2008). Cures are not usually seen, however, and patients
require on-going therapy. Hence, there is a great need to
continue to develop effective drugs for the treatment of CTCLs.
Mounting evidence indicates that an inflammatory environ-
ment is a participatory component of tumor development
(Mantovani et al., 2008). In one of our established murine
models of CTCLs, C57BL/6 mice injected with MBL2
T-lymphoma cells in the ear can be induced to develop a
cutaneous lymphoma in the setting of an inflammatory
response generated by a single topical application of 2,4-Di-
nitro-fluorobenzene (Wu et al., 2011). In this model, tumors
do not develop in these animals in the absence of 2,4-Di-
nitro-fluorobenzene application or when mice are treated with
corticosteroids, thus underscoring the importance of the
inflammatory microenvironment in this model of CTCL.
Moreover, inflammatory macrophages appear to have a critical
role, as depletion of macrophages markedly reduces the size
of the T-cell tumors (Wu et al., 2014)
Gallium is a group IIIa metal that shares certain chemical
similarities with iron (III). These properties enable gallium to
bind to the iron transport protein transferrin and to be taken up
by cells via transferrin receptor (TfR)-mediated endocytosis of
transferrin-gallium (Tf-Ga) complexes (Larson et al., 1980,
Harris and Pecoraro, 1983, Chitambar and Zivkovic, 1987).
Lymphoma cells are known to express high densities of cell
surface TfRs, thus making them selective targets for Tf-Ga
(Kvaloy et al., 1984, Chitambar et al., 1989). In contrast to
lymphoma cells, normal resting lymphocytes do not express
cell surface TfRs and are thus not targeted by Tf-Ga (Chitambar
et al., 1989). Tf-Ga interferes with the cellular uptake of
transferrin-iron, producing a state of cellular iron deprivation,
which can induce apoptosis (Chitambar et al., 1989). Malignant
cells have a greater requirement for iron compared with normal
cells, rendering them more susceptible to iron deprivation
(Richardson et al., 2009). The action of gallium extends
beyond interfering with TfR-mediated iron uptake; it inhibits
iron-dependent ribonucleotide reductase (deoxyribonucleotide
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synthesis), iron-dependent mitochondrial function, and other
processes in the cells, ultimately culminating in cell death
(Chitambar, 2012; Chitambar and Antholine, 2013). Gallium
also has significant anti-inflammatory and immunosuppressive
activities (Chitambar, 2010). The anti-inflammatory action of
gallium appears to involve the downregulation of inflammatory
T cells and macrophages, as well as possible interference with
matrix metalloproteinases. Because many iron compounds are
proinflammatory, the ability of gallium to act as a nonfunctional
iron mimetic may contribute to its anti-inflammatory activity.
Clinical trials have shown gallium nitrate (GaN), a first
generation gallium compound, to have significant antineo-
plastic activity in B-cell non-Hodgkin’s lymphoma (Straus,
2003). However, drug resistance to GaN may be encountered,
thus limiting its anti-tumor efficacy in some patients. Our
recent studies have shown that gallium maltolate (GaM), a
next generation of gallium compound, displays greater cytoto-
xicity compared with GaN against a panel of lymphoma cell
lines, including lymphoma cells resistant to growth inhibition
by GaN (Chitambar et al., 2007). In contrast to GaN, which is
a simple metal salt, GaM consists of three maltolate ligands
bidentately bound to a central gallium atom in a propeller-like
arrangement (Chitambar et al., 2007). Gallium’s anti-inflam-
matory properties may be relevant to CTCLs, as our studies
have shown that CTCL develops in a background of inflam-
matory changes in the skin. Beyond a single case report of a
marked response to GaN in a patient with peripheral T-cell
lymphoma refractory to conventional therapy (Huang et al.,
2005), there are limited data and research on the efficacy of
gallium compounds in CTCLs. In the present study, we
examined the antineoplastic efficacy of GaM in vitro and
in vivo in preclinical murine models of CTCLs and investi-
gated the molecular mechanisms that mediate the anti-tumor
activity of this metallocompound.
RESULTS
Cytotoxic activity of GaM in CTCL cells
Hut78 and HH are both CTCL cell lines that were established
from human CTCL patients. Because TfR-mediated endocyto-
sis of Tf-Ga is the initial step in gallium-mediated cell death,
we first examined whether TfR was present on the surface of
Hut78 and HH cells. Using anti-CD71 (TfR) antibody, we
detected the homogeneous expression of TfR on both cell lines
by flow cytometry (Supplementary Figure S1 online), indicat-
ing that these cells may be selectively targeted by TfR-Ga
through TfR-ligand engagement. Next, we exposed both
cultured cell lines to GaM at increasing concentrations
(Figure 1a). Both CTCL cell lines exhibited dose-dependent
cytotoxicity with GaM. Of note, a slight proliferative effect of
GaM was seen after day 1 of treatment at 100mM, but
complete killing of Hut78 cells was seen after 3 days of
incubation. The ability of gallium to mimic iron, an essential
element for cell growth, may account for the initial prolif-
erative effects of low-dose GaM. Although HH cells were also
sensitive to GaM exposure, they required a higher concentra-
tion of GaM and a longer incubation period for complete
killing (Figure 1a). In the flow cytometry–based apoptosis
assay, Hut78 cells showed marked increases of annexin V or
7-AAD positivity after 1 day exposure to GaM at 100mM
(47.5% in GaM vs. 10.9% in phosphate-buffered saline (PBS
control; Figure 1b). Interestingly, we noticed that GaM
displayed only slight toxicity against HaCat keratinocyte cells
(Supplementary Figure S2 online), suggesting that GaM may
have selective toxicity toward the two malignant T-cell lines.
A Seahorse XF24 Extracellular Flux Analyzer (Seahorse
Bioscience, North Billerica, MA) was utilized to measure oxygen
consumption in CTCL cell lines. Incubation of HuT78 cells
with increasing concentrations of GaM over 8 hours resulted
in a dose-dependent decrease in the cellular oxygen con-
sumption rate before measurable changes in cell death could
be detected (Figure 1c), suggesting that an early event in
gallium-induced tumor cell death involves inhibition of mito-
chondrial respiratory function, and thus cellular metabolism.
Inhibition of tumor growth by GaM in CTCL mouse models
In order to determine whether GaM can block tumor growth
in vivo, we established xenograft CTCL mouse models through
the subcutaneous (SC) implantation of CTCL cells, either
Hut78 or HH cells, in the flank skin of Nod-Scid IL-2 g-chain
knockout (NSG) mice. Tumors were apparent after 2 weeks
with most growth occurring during the third and fourth weeks.
To observe the treatment effect by GaM, we injected GaM at
the same site with a daily dosage of 400mg per mouse for
5 days 1 day after tumor cell inoculation. Four weeks after
implantation, mice were killed and examined (Figure 2a).
Solid tumors were found in SC area in the mice in PBS-treated
group, whereas tumors were rarely found in GaM-treated
mice (Figure 2b). Significant decreases in tumor formation
were revealed in both Hut78 and HH cell line experiments
(Supplementary Figure S3 online, Hut78, P¼0.0021, HH,
P¼0.0061).
In addition, we sought to determine the anti-tumor effect of
GaM on established CTCL tumors. Therefore, instead of on
day 2, we started GaM treatment on day 8 or 15 after tumor
implantation as indicated (Figure 2a). Mice were killed
4 weeks after implantation. With treatment starting at day 8,
tumor growth was greatly inhibited as confirmed by hematox-
ylin and eosin staining (Figure 2c). Even with treatment starting
at day 15, the GaM-treated tumors showed a significant
reduction in size compared with PBS treatment (P¼ 0.0415),
although tumor growth was only partially inhibited (Figure 2d
and e). Thus, even in established tumors, GaM treatment
can effectively inhibit growth of CTCL tumors in NSG mice
(Figure 2d and e).
Decreased tumor vascularization with GaM treatment in tumor-
bearing mice
To understand the impact of GaM treatment on the tumor
environment, we first assessed tumor vascularity in Hut78
tumor tissues isolated from PBS or GaM-treated tumor-bearing
mice. Immunofluorescent staining showed a significant decrease
in CD31, a recognized marker for vascular endothelial
cells, in the tumors from GaM-treated mice (Supplementary
Figure S4a and b online). Although positive signals high-
lighting both small vessels and individual cells were frequently
observed amidst condensed tumor area in the PBS control
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group, we rarely identified equivalent signals in GaM-treated
tumors, suggesting that angiogenesis was reduced in GaM-
treated mice. Staining with antibodies against podoplanin, the
lymphatic marker, or F4/80 (a macrophage marker) did not
reveal differences between GaM-treated and control groups
(Supplementary Figure S4 online). Thus, GaM treatment results
in marked decreases in CD31 staining, suggesting that GaM
interferes with tumor angiogenesis but not lymphangiogenesis
(which may have a role in tumor spread to lymph nodes) or
numbers of macrophages (which in prior studies were shown
to potentially influence CTCL development (Sugaya et al.,
2012; Wu et al., 2014).
GaM exposure induces production of cytotoxic inflammatory
cytokines in Hut78 cells
In order to determine whether administration of GaM had
broad systemic effects on host immunity, we analyzed major
immune cell populations (macrophages and neutrophils) in
spleens from mice after GaM treatment. Spleens were col-
lected from the mice in the aforementioned treatment groups.
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Figure 1. GaM has cytotoxic effects on cultured CTCL cells. (a) The trypan blue exclusion assay measuring the effect of GAM exposure on the growth
rate of Hut78 and HH cells. Cells were incubated with GaM at indicated concentrations, and live cells were counted after trypan blue staining on day 0, 1, 2,
and 3. (b) The apoptosis assay for GaM-treated Hut78 cells. Cultured Hut78 cells were exposed to GaM at 100mM for 1 day. Cells were stained with
Annexin V and 7-AAD and analyzed by FACS. (c) GaM produces a dose-dependent decrease in the cellular oxygen consumption rate in HuT78 cells. Cells
were incubated with GaM for 8 hours prior to assay. CTCL, cutaneous T-cell lymphoma; GaM, gallium maltolate.
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fluorescence-activated cell sorting (FACS) analysis revealed an
equal percentage of CD45þ cells in GaM and control groups.
Further analysis for the two major immune populations,
F4/80þ macrophages and Gr-1þ neutrophils, also did not
reveal any differences among the treatment groups (Supple-
mentary Figure S5 online).
Although broad systemic changes in host immunity were
not observed, local changes in host immunity via regulatory
cytokines might explain GaM anti-tumor activity. Therefore, to
detect GaM-induced changes after GaM treatment, we per-
formed pathway-focused microarray analysis of inflammatory
cytokines on RNA extracted from Hut78 cells 1 day after
treatment with either GaM or PBS. Interestingly, we detected
upregulation of proinflammatory cytokines and receptors,
such as CEBPB, CX3CR1, CXCL11, IL17C, IL1A, IL36A,
TNF, XCR1, and, remarkably, IL-13. On the contrary, down-
regulation of IL-10 was detected in GaM-treated Hut78 cells,
when compared with PBS control samples (Figure 3 and
Supplementary Table S1 online). Of note, the Th1 IFN-g-
induced chemokines, CXCL10 (IP-10) and CXCL11, were both
significantly upregulated with GaM treatment. It has been
demonstrated that CXCL10 and CXCL11 are potent angiostatic
proteins, whereas IL-10 promotes angiogenesis. Thus, the
reduced vascularity observed in GaM-treated tumors may be
mediated by regulation of chemokines and cytokines that
regulate angiogenesis.
GaM-induced apoptosis involves the oxidative stress and p53
pathways
Given that direct cytotoxicity observed in tumor cells follow-
ing GaM exposure, we further explored the involvement of
signal transduction pathways in CTCLs following GaM treat-
ment. We utilized mRNA expression microarrays that target
genes for 10 common pathways important for developmental,
immunological, metabolic, and stress-activated processes. The
transcriptional profiles of Hut78 cells treated with GaM and
PBS were compared in order to analyze differential activation
of signaling pathways (Supplementary Table S2 online).
Following GaM treatment, we identified four genes within
the oxidative stress pathway and three genes within the p53
pathway (Figure 4a) that were differentially expressed. In
particular, expression of heme oxygenase 1 (Exner et al.,
2004), a fundamental gene involved in the activation of the
oxidative stress pathway, was increased in GaM-treated Hut78
cells versus controls by both real-time reverse-transcriptase–
PCR and western blot (Supplementary Figure S6 online).
CDKN1A (p21; Harper et al., 1993) and GADD45A
(Salvador et al., 2013), two p53 pathway genes found to be
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Figure 2. Administration of GaM inhibits CTCL tumor growth in mouse models. (a) Schematic GaM treatment regimen. Hut78 cells were implanted SC in NSG
mice on day 1. GaM was administered by peritumoral injection at a dosage of 400mg per mouse/day for 5 consecutive days starting on day 2 (1st wk), day 8 (2nd
wk), or day 15 (3rd wk), respectively. Equal volume of PBS (200ml) was injected instead of GaM for 1st wk as control. (b) Representative pictures of 1st wk GaM-
and PBS-treated mice. Red arrows indicate subcutaneous areas where tumor formation was seen in PBS-treated, whereas not in GaM-treated mice. (c) H&E
staining for maximum cross-sections of tumors isolated from GaM-treated (2nd wk) and control groups. (d) Sizes and (e) images of flank tumors 4 weeks after
implantation. Student’s t-test was performed between each GaM-treated group and PBS control. CTCL, cutaneous T-cell lymphoma; GaM, gallium maltolate;
H&E, hematoxylin and eosin.
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7–8-fold upregulated, mediate growth arrest following cellular
stress. BTG2, a member of a family that appears to have anti-
proliferative properties (Rouault et al., 1996), was also found
to be B3-fold upregulated (Figure 4a). In addition, because
GADD45A is believed to activate the p38/JNK (c-Jun N-term-
inal kinase) pathway and lead to apoptosis when responding
to environmental stress, we measured phosphorylated p38 in
CTCL cells incubated with GaM. Western blot showed an
increase in phospho-p38 in Hut78 cells after 24 hours in
culture with 100mM GaM (Figure 4b). Thus, GaM clearly
alters key signaling pathways that may facilitate apoptosis of
CTCL cells.
DISCUSSION
GaM has gained attention for its potent anti-inflammatory and
anti-tumor activities. It shows high bioavailability in multiple
formulations including oral, topical, and other routes of
administration, making it an attractive therapeutic agent.
Compared with GaN, GaM shows significantly greater cyto-
toxicity in tumor cells in vitro, and most importantly it is
capable of inducing apoptosis in cells that are resistant to GaN
(Chitambar et al., 2007). Herein, we report that GaM effec-
tively induced CTCL cell apoptosis and inhibited CTCL tumor
formation in an animal model using bona fide human CTCL
cells.
Although gallium shares similarities with iron with respect
to ionic radius, binding to transferrin and certain other
iron-binding proteins, and incorporation into cells by the
TfR-mediated pathway, it does not appear to have a functional
role in mammalian cells. Instead, gallium interferes with
the function of iron-containing cellular proteins, leading to a
disruption of iron homeostasis in cells. Because malignant
cells exhibit a greater metabolic requirement for iron, gallium
compounds are more cytotoxic to proliferating malignant cells
relative to normal cells. We have assessed the toxicity of GaM
toward HaCaT cells (Supplementary Figure S2 online), a non-
malignant keratinocyte cell line, and found that GaM showed
far less toxicity toward HaCaT cells. When administered in
mouse skin, GaM did not induce erosion or necrosis in normal
skin, although we did observe mild skin edema and redness
(data not shown). These observations suggest that GaM-based
anti-tumor therapy may have limited toxicity to surrounding
normal cells.
A clinically useful CTCL treatment must be able to reduce
the growth of established tumors. We used a human CTCL
xenograft model in NSG mice to determine the efficacy of
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GaM treatment at different time periods after tumor inocula-
tion. Of note, the results showed that up to 60% of mice were
protected from tumor formation by GaM administration in the
first week treatment group. Moreover, reductions in tumor size
were observed in the 2nd and even in the 3rd week treatment
groups, validating the effectiveness of GaM in established
CTCL tumors.
Inflammatory cytokines are important molecules that med-
iate both tumor growth and host anti-tumor immunity. Tumor
cells usually enhance the production of specific types of
cytokines that help the tumor cells survive host immune
responses. In this case, we detected reproducible changes in
the inflammatory cytokine profile of GaM-treated CTCL cells.
We found that GaM treatment increased the IFN-g-inducible
chemokines, CXCL10 and CXCL11, which attract CXCR3þ
Th1 lymphocytes and inhibit angiogenesis (Tannenbaum
et al., 1998; Hensbergen et al., 2005). Of note, CXCL10
(IP-10) has been described as a potent angiostatic factor that
regulates tumor angiogenesis and inhibits tumorigenesis and
tumor metastasis (Arenberg et al., 1996). Expression of IL-13, a
cytokine that promotes host immune surveillance and tumor
immunity (Serve et al., 1996, Volpert et al., 1998), was also
greatly induced following GaM treatment. Finally, IL-10, a
Th2 cytokine that promotes angiogenesis, was found to be
downregulated following GaM treatment. IL-10 has been
shown to be upregulated in the setting of clinical progres-
sion of mycosis fungoides (Asadullah et al., 1996). Thus, the
cytokine profile shift that we observed with GaM treatment
would help create an unfavorable environment for tumor
growth by decreasing angiogenesis and increasing migration
of anti-tumor immune cells into the tumor.
In exploring downstream signaling pathways that may be
involved in apoptosis of CTCL cells induced by GaM, we
identified activation of representative genes in both oxidative
stress and p53 pathways in Hut78 cells with GaM treatment.
Oxidative stress driven by inflammation results in an excess of
free radical species, leading to cellular injury and death.
Specifically, the marked upregulation of heme oxygenase 1,
one of the most important genes in the oxidative stress
pathway, was confirmed in GaM-treated Hut78 CTCL cells.
Upregulation of heme oxygenase 1 serves as an adaptive
mechanism to protect cells from oxidative damage, suggesting
that GaM can induce cellular defensive mechanisms as a
byproduct of cytotoxicity. We also identified involvement of
the p53 pathway following GaM treatment. As a representa-
tive gene for p53 pathway, GADD45A was increased at
transcriptional levels following stressful growth arrest condi-
tions and treatment with DNA-damaging agents (Salvador
et al., 2013). The protein encoded by this gene responds to
environmental stressors by activating the p38/JNK pathway
(Zhu et al., 2009), which we confirmed by detection of
phosphorylated p38 in GaM-treated CTCL cells.
In summary, our results clearly demonstrate that GaM treat-
ment in vivo blocks growth of (established) human CTCL
tumors in xenograft models. Mechanistically, multiple immu-
nologic and metabolic changes following administration of
GaM produce an environment that favors anti-tumor res-
ponses and increases cellular metabolic stress. Agents that
work via multiple mechanisms may decrease the potential for
cancer cells to develop resistance. Further investigation of
gallium-containing compounds, including GaM, is indicated
in order to improve the therapeutic arsenal for advanced
CTCL.
MATERIALS AND METHODS
Animals and cell lines
Female NSG (stock number 005557) mice (8–10-week old) were
purchased from Jackson Laboratory (Bar Harbor, ME). Mice were
housed at the Medical College of Wisconsin in the barrier animal
room with sterilization of food, bedding, and supplies. All animal
experiments were conducted in accordance with the guidelines and
approval of the Institutional Animal Care and Usage Committee
(IACUC) at the Medical College of Wisconsin. Human CTCL cell
lines, Hut78 and HH, were purchased from ATCC (Manassas, VA; Cat
number: TIB-161 and CRL-2105). Hut78 cells were cultured in
Iscove’s Modified Dulbecco’s medium. HH cells were cultured in
RPMI-1640 medium.
Flow cytometric analysis and apoptosis detection
TfR antibodies (anti-human CD71 and anti-mouse CD71), anti-CD45,
anti-mouse F4/80, and anti-mouse Gr-1 were purchased from
BioLegend (San Diego, CA). The Apoptosis detection PE kit was
purchased from eBioscience (San Diego, CA). In order to detect
surface markers, cells were washed once in PBS, once in FACS buffer,
and resuspended in FACS buffer at 5 105 ml 1. Cells were then
incubated with antibodies at 4 1C for 30 min and washed with FACS
buffer. Cell preparation was analyzed on a BD FACSCalibur flow
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cytometer (San Jose, CA). For apoptosis detection, GAM-treated/
untreated cells were washed once in PBS, once in 1x Binding Buffer,
and resuspended in 1x Binding Buffer at 5 106 ml 1. PE-conjugated
Annexin V (5ml) was added to 100ml of the cell suspension and
incubated for 10–15 minutes at room temperature. Cells were washed
in 1x Binding Buffer and resuspended in 200ml of 1x Binding Buffer.
A volume of 5ml of 7-AAD Viability staining solution was added, and
the cells were immediately analyzed by flow cytometry.
Mitochondrial oxygen consumption
The effects of GaM on mitochondrial function was assessed by
measuring the oxygen consumption rate in intact HuT78 cells using
a Seahorse XF24 Extracellular Flux Analyzer according to the
manufacturer’s recommendations (Dranka et al., 2011). Cells were
incubated in tissue culture with increasing concentrations of GaM for
8 hours and then collected, washed in Dulbecco’s PBS, and resus-
pended in unbuffered RPMI-1640 assay media containing 2 mM
L-glutamine, 5 mM sodium pyruvate, pH 7.4, without sodium bicar-
bonate (Life Technologies; Grand Island, NY). Cells (750,000 cells per
well) were plated in Seahorse Bioscience V7 tissue culture plates.
One hundred microliters of cell suspension in non-buffered assay
media was added per well to be measured. Prior to seeding, the assay
plates were coated with Cell-Tak (BD Biosciences; San Jose, CA).
Cells were centrifuged to the bottom of the plate at 250 g for
5 minutes prior to the addition of an additional 400ml of assay media.
Establishment of tumor mouse models and GaM treatment
Mice were sedated with IP injection of ketamine/xylazine solution.
PBS–washed CTCL cells (Hut78 or HH) (1 106 per mouse) were
injected into the SC space in the center of the shaved skin using a 28 g
needle. Mice were monitored during recovery from anesthesia and
moved back to normal housing. Tumors were visually examined
twice a week until the end point in the 4th week after implantation.
For in vivo GaM treatment, daily injections were performed for
5 days. Depending on the initiation of GaM administration, three
treatment regimens were used: 1st week, 2nd week, and 3rd week
treatment, which started on day 2, 8, and 15, respectively, after tumor
cell implantation on day 1, were performed (Figure 2a). All GaM
treatments involved careful injection of GaM (five consecutive daily
injection, 400mg per injection) into the SC tissue around the site of
tumor implantation (peritumoral injection) while avoiding the tumor
mass itself. For the control group, equal volumes of PBS (200ml) were
injected in similar manner.
Western blot
CTCL cells treated with and without GaM were collected, lysed, and
centrifuged to remove cellular debris. The protein content of super-
natants was measured by the bicinchoninic acid protein assay (Pierce,
Rockford, IL). Samples were resolved by NuPAGE Bis-Tris precast gel
and transferred into a nitrocellulose membrane using a Transblot
system (Life Technologies). Membranes were incubated with specific
primary antibody to p38, phosphorylated p38, HO-1, and glycer-
aldehyde-3-phosphate dehydrogenase. Washed membranes were
incubated in appropriate secondary antibody conjugated to horse-
radish peroxidase, immersed in Pierce ECL chemiluminescence
detection solution (Pierce), and recorded by imaging with a
Molecular Imager Gel Doc XRþ system with Image Lab Software
(Bio-Rad, Hercules, CA).
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